NCT02639286View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions
Lipodystrophy
Interventions
DRUG

ISIS 304801

300 mg of ISIS 304801 administered as SC

DRUG

Placebo

Placebo administered via SC

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02639286 - Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension | Biotech Hunter | Biotech Hunter